NCT03473730View on ClinicalTrials.gov

Daratumumab in Treating Patients with Muscle Invasive Bladder Cancer or Metastatic Kidney Cancer

EARLY_PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 29, 2018

Primary Completion Date

January 27, 2025

Study Completion Date

January 27, 2025

Conditions

Bladder Urothelial CarcinomaClear Cell Renal Cell CarcinomaMalignant Urinary System NeoplasmMetastatic Kidney CarcinomaStage IV Renal Cell Cancer AJCC V8

Interventions

PROCEDURE

Biopsy

Undergo biopsy

BIOLOGICAL

Daratumumab

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

PROCEDURE

Metastasectomy

Undergo metastasectomy

PROCEDURE

Nephrectomy

Undergo nephrectomy

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors

collaborator

Janssen Research & Development, LLC

INDUSTRY

collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT03473730 - Daratumumab in Treating Patients with Muscle Invasive Bladder Cancer or Metastatic Kidney Cancer | Biotech Hunter | Biotech Hunter